4,065 Shares in Insulet Corporation $PODD Purchased by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. purchased a new position in Insulet Corporation (NASDAQ:PODD) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 4,065 shares of the medical instruments supplier’s stock, valued at approximately $619,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. State Street Corp lifted its stake in Insulet by 2.1% during the fourth quarter. State Street Corp now owns 3,155,489 shares of the medical instruments supplier’s stock valued at $896,916,000 after purchasing an additional 65,317 shares during the last quarter. Geode Capital Management LLC grew its position in Insulet by 2.1% in the fourth quarter. Geode Capital Management LLC now owns 2,006,413 shares of the medical instruments supplier’s stock worth $568,274,000 after buying an additional 41,019 shares during the last quarter. Invesco Ltd. increased its holdings in shares of Insulet by 10.5% in the fourth quarter. Invesco Ltd. now owns 1,480,562 shares of the medical instruments supplier’s stock valued at $420,835,000 after buying an additional 141,167 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in shares of Insulet by 462.7% in the first quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier’s stock valued at $258,088,000 after buying an additional 1,011,369 shares in the last quarter. Finally, Norges Bank acquired a new stake in shares of Insulet during the 4th quarter valued at $300,794,000.

Insulet News Roundup

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet’s latest quarterly results exceeded expectations, with earnings of $1.66 per share versus the $1.47 consensus estimate and revenue of $801.7 million versus $787.4 million expected. Revenue increased 23.5% year over year. Why Insulet PODD Stock Is Down Today
• Positive Sentiment: Insulet insiders have predominantly purchased shares during the past six months, including sizable purchases by CEO Ashley McEvoy and other directors. Such buying may signal management confidence following the stock’s decline. Why Insulet PODD Stock Is Down Today
• Neutral Sentiment: Analyst coverage remains generally favorable, with recent Buy-equivalent ratings and a reported median price target of $219.50. However, some recent targets are lower, including $172 from Citigroup and $180 from Evercore ISI, reflecting more cautious near-term expectations. Why Insulet PODD Stock Is Down Today
• Negative Sentiment: The main fundamental concern is Insulet’s softer forward outlook. Lower full-year Omnipod growth guidance and a weaker third-quarter forecast suggest slowing U.S. momentum, overshadowing the earnings and revenue beat. Why Insulet PODD Stock Is Down Today
• Negative Sentiment: Multiple law firms are promoting a securities class action against Insulet and certain executives, alleging investors were harmed by disclosures concerning defective Omnipod manufacturing controls. The allegations have not been proven, but the litigation adds legal, regulatory and reputational risk. The reported lead-plaintiff deadline is August 31, 2026. Insulet Class Action Announcement
• Negative Sentiment: Earlier disclosure of a voluntary correction involving certain Omnipod products, reportedly affecting approximately 7 million Pods and potentially causing insulin under-delivery, continues to raise concerns about manufacturing execution and future costs. Why Insulet PODD Stock Is Down Today

Insider Buying and Selling

In other Insulet news, Director Timothy C. Stonesifer acquired 2,790 shares of the business’s stock in a transaction that occurred on Wednesday, June 3rd. The shares were purchased at an average price of $143.51 per share, with a total value of $400,392.90. Following the completion of the transaction, the director owned 9,041 shares in the company, valued at $1,297,473.91. The trade was a 44.63% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.36% of the company’s stock.

Insulet Price Performance

NASDAQ PODD opened at $139.70 on Tuesday. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.48 and a quick ratio of 1.83. The firm has a market capitalization of $9.69 billion, a price-to-earnings ratio of 26.11, a price-to-earnings-growth ratio of 1.13 and a beta of 1.10. The company has a 50 day simple moving average of $154.96 and a 200-day simple moving average of $187.34. Insulet Corporation has a 52-week low of $126.40 and a 52-week high of $354.88.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 EPS for the quarter, beating the consensus estimate of $1.47 by $0.19. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The business had revenue of $801.70 million for the quarter, compared to analysts’ expectations of $787.39 million. During the same period in the previous year, the company posted $1.17 EPS. Insulet’s revenue was up 23.5% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.460- EPS. Equities research analysts predict that Insulet Corporation will post 6.51 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. UBS Group cut their price objective on Insulet from $174.00 to $150.00 and set a “neutral” rating on the stock in a report on Thursday, August 6th. The Goldman Sachs Group restated a “buy” rating and set a $205.00 price target on shares of Insulet in a report on Wednesday, May 27th. Bank of America reduced their price target on shares of Insulet from $288.00 to $208.00 and set a “buy” rating for the company in a research report on Monday, May 18th. Rothschild & Co Redburn reaffirmed a “neutral” rating and issued a $220.00 price objective (down from $380.00) on shares of Insulet in a research note on Friday, April 24th. Finally, Raymond James Financial reiterated an “outperform” rating and set a $180.00 price objective on shares of Insulet in a research report on Thursday, August 6th. Fourteen analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $195.40.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.